Journal article 328 views
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
Robert J. Motzer,
Bernard Escudier,
Saby George,
Hans J. Hammers,
Sandhya Srinivas,
Scott S. Tykodi,
Jeffrey A. Sosman,
Elizabeth R. Plimack,
Giuseppe Procopio,
David F. McDermott,
Daniel Castellano,
Toni K. Choueiri,
Frede Donskov,
Howard Gurney,
Stéphane Oudard,
Martin Richardet,
Katriina Peltola,
Ajjai S. Alva,
Michael Carducci,
John Wagstaff,
Christine Chevreau,
Satoshi Fukasawa,
Yoshihiko Tomita,
Thomas C. Gauler,
Christian K. Kollmannsberger,
Fabio A. Schutz,
James Larkin,
David Cella,
M. Brent McHenry,
Shruti Shally Saggi,
Nizar M. Tannir
Cancer, Volume: 126, Issue: 18, Pages: 4156 - 4167
Swansea University Author: John Wagstaff
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1002/cncr.33033
Abstract
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
| Published in: | Cancer |
|---|---|
| ISSN: | 0008-543X 1097-0142 |
| Published: |
Wiley
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa55409 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| College: |
Faculty of Medicine, Health and Life Sciences |
|---|---|
| Issue: |
18 |
| Start Page: |
4156 |
| End Page: |
4167 |